New Zealand markets closed

OCGN Jan 2024 15.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
At close: 09:30AM EDT
Full screen
Previous close0.0500
Open0.0500
Bid0.0000
Ask0.0000
Strike15.00
Expiry date2024-01-19
Day's range0.0500 - 0.0500
Contract rangeN/A
Volume9
Open interest593
  • GlobeNewswire

    Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board

    MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Connie Collingsworth, former Chief Operating Officer of the Bill and Melinda Gates Foundation, will join the Company’s Business Advisory Board (BAB). The BAB was established in June 2023 to assist in driving public/private partnerships with

  • GlobeNewswire

    Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023

    MALVERN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a panel at the annual Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in NYC. On the panel, Dr. Musun

  • GlobeNewswire

    Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

    Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity (BCVA) and Multi-Luminance Mobility Testing (MLMT), as well as positive trends in Low-Luminance Visual Acuity (LLVA) among treated eyes83% (10/12) of subjects demonstrated stabilization or improvement in treated eye either on BCVA or LLVA or MLMT scores from baselineNotably, 86% (6/7) of RHO mutatio